Integration of Epigenetic Mechanisms into Non-Genotoxic Carcinogenicity Hazard Assessment: Focus on DNA Methylation and Histone Modifications

被引:26
作者
Desaulniers, Daniel [1 ]
Vasseur, Paule [2 ]
Jacobs, Abigail [3 ]
Aguila, M. Cecilia [4 ]
Ertych, Norman [5 ]
Jacobs, Miriam N. [6 ]
机构
[1] Hlth Canada, Hazard Identificat Div, Environm Hlth Sci & Res Bur, AL 2203B, Ottawa, ON K1A 0K9, Canada
[2] Univ Lorraine, CNRS, LIEC, F-57070 Metz, France
[3] US FDA, Independent Time Publicat, Rockville, MD 20857 USA
[4] US FDA, Div Human Food Safety, Ctr Vet Med, Dept Hlth & Human Serv,Toxicol Team, Rockville, MD 20852 USA
[5] German Fed Inst Risk Assessment, German Ctr Prot Lab Anim Bf3R, Diedersdorfer Weg 1, D-12277 Berlin, Germany
[6] Publ Hlth England, Ctr Radiat Chem & Environm Hazards, Chilton OX11 0RQ, England
关键词
epigenetics; DNA methylation; histone modifications; carcinogens; non-genotoxic; risk assessment; mode of action; IATA; AOP; HAMSTER EMBRYO CELLS; TUMOR-SUPPRESSOR GENES; CONSTITUTIVE ANDROSTANE RECEPTOR; MESSENGER-RNA EXPRESSION; GLOBAL DNA; GENOME-WIDE; ARSENIC EXPOSURE; E-CADHERIN; OXIDATIVE STRESS; HUMAN CANCER;
D O I
10.3390/ijms222010969
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Epigenetics involves a series of mechanisms that entail histone and DNA covalent modifications and non-coding RNAs, and that collectively contribute to programing cell functions and differentiation. Epigenetic anomalies and DNA mutations are co-drivers of cellular dysfunctions, including carcinogenesis. Alterations of the epigenetic system occur in cancers whether the initial carcinogenic events are from genotoxic (GTxC) or non-genotoxic (NGTxC) carcinogens. NGTxC are not inherently DNA reactive, they do not have a unifying mode of action and as yet there are no regulatory test guidelines addressing mechanisms of NGTxC. To fil this gap, the Test Guideline Programme of the Organisation for Economic Cooperation and Development is developing a framework for an integrated approach for the testing and assessment (IATA) of NGTxC and is considering assays that address key events of cancer hallmarks. Here, with the intent of better understanding the applicability of epigenetic assays in chemical carcinogenicity assessment, we focus on DNA methylation and histone modifications and review: (1) epigenetic mechanisms contributing to carcinogenesis, (2) epigenetic mechanisms altered following exposure to arsenic, nickel, or phenobarbital in order to identify common carcinogen-specific mechanisms, (3) characteristics of a series of epigenetic assay types, and (4) epigenetic assay validation needs in the context of chemical hazard assessment. As a key component of numerous NGTxC mechanisms of action, epigenetic assays included in IATA assay combinations can contribute to improved chemical carcinogen identification for the better protection of public health.</p>
引用
收藏
页数:95
相关论文
共 651 条
  • [1] Nutrition, one-carbon metabolism and arsenic methylation
    Abuawad, Ahlam
    Bozack, Anne K.
    Saxena, Roheeni
    Gamble, Mary, V
    [J]. TOXICOLOGY, 2021, 457
  • [2] DNA sequence-dependent activity and base flipping mechanisms of DNMT1 regulate genome-wide DNA methylation
    Adam, Sabrina
    Anteneh, Hiwot
    Hornisch, Maximilian
    Wagner, Vincent
    Lu, Jiuwei
    Radde, Nicole E.
    Bashtrykov, Pavel
    Song, Jikui
    Jeltsch, Albert
    [J]. NATURE COMMUNICATIONS, 2020, 11 (01)
  • [3] Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
    Al-Khadairi, Ghaneya
    Decock, Julie
    [J]. CANCERS, 2019, 11 (07)
  • [4] Allera C, 1997, J BIOL CHEM, V272, P10817
  • [5] The molecular hallmarks of epigenetic control
    Allis, C. David
    Jenuwein, Thomas
    [J]. NATURE REVIEWS GENETICS, 2016, 17 (08) : 487 - 500
  • [6] Heterogeneous DNA Methylation Patterns in the GSTP1 Promoter Lead to Discordant Results between Assay Technologies and Impede Its Implementation as Epigenetic Biomarkers in Breast Cancer
    Alnaes, Grethe I. Grenaker
    Ronneberg, Jo Anders
    Kristensen, Vessela N.
    Tost, Joerg
    [J]. GENES, 2015, 6 (03): : 878 - 900
  • [7] Is the current product safety assessment paradigm protective for epigenetic mechanisms?
    Alyea, Rebecca A.
    Moore, Nigel P.
    LeBaron, Matthew J.
    Gollapudi, B. Bhaskar
    Rasoulpour, Reza J.
    [J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2012, 66 (03) : 207 - 214
  • [8] The dark side of histones: genomic organization and role of oncohistones in cancer
    Amatori, Stefano
    Tavolaro, Simona
    Gambardella, Stefano
    Fanelli, Mirco
    [J]. CLINICAL EPIGENETICS, 2021, 13 (01)
  • [9] Epigenetic Applications in Adverse Outcome Pathways and Environmental Risk Evaluation
    Angrish, Michelle M.
    Allard, Patrick
    McCullough, Shaun D.
    Druwe, Ingrid L.
    Chadwick, Lisa Helbling
    Hines, Erin
    Chorley, Brian N.
    [J]. ENVIRONMENTAL HEALTH PERSPECTIVES, 2018, 126 (04) : 045001 - 1
  • [10] [Anonymous], 2016, Treatment manual., VPP, P1